14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $126.97 $164.60 Friday, 3rd May 2024 BGNE stock ended at $162.25. This is 0.148% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 2.00% from a day low at $159.32 to a day high of $162.51.
90 days $126.97 $184.80
52 weeks $126.97 $257.72

Historical BeiGene Ltd prices

Date Open High Low Close Volume
May 03, 2024 $162.51 $162.51 $159.32 $162.25 193 858
May 02, 2024 $160.99 $164.60 $158.81 $162.01 266 521
May 01, 2024 $154.30 $157.89 $154.30 $156.53 174 450
Apr 30, 2024 $155.00 $156.64 $150.29 $153.94 205 279
Apr 29, 2024 $155.00 $157.89 $153.33 $156.53 184 105
Apr 26, 2024 $152.11 $154.47 $150.73 $153.58 204 920
Apr 25, 2024 $148.40 $152.83 $146.16 $148.56 406 915
Apr 24, 2024 $143.45 $146.22 $141.78 $144.12 215 535
Apr 23, 2024 $135.75 $142.22 $134.68 $138.99 201 776
Apr 22, 2024 $130.55 $133.08 $129.96 $130.94 152 563
Apr 19, 2024 $130.00 $130.85 $126.97 $129.52 250 094
Apr 18, 2024 $131.40 $136.00 $131.40 $131.96 123 663
Apr 17, 2024 $134.40 $134.40 $131.28 $131.86 199 968
Apr 16, 2024 $137.28 $137.71 $133.71 $134.05 307 547
Apr 15, 2024 $140.68 $142.63 $137.38 $138.40 225 888
Apr 12, 2024 $145.00 $146.81 $140.08 $141.30 136 667
Apr 11, 2024 $147.62 $148.92 $145.45 $146.13 240 538
Apr 10, 2024 $150.34 $150.97 $147.98 $149.76 272 223
Apr 09, 2024 $153.70 $155.37 $150.84 $154.02 115 201
Apr 08, 2024 $148.84 $151.52 $148.50 $149.75 106 951
Apr 05, 2024 $149.57 $151.45 $148.00 $150.03 89 025
Apr 04, 2024 $153.26 $153.26 $149.30 $149.57 80 379
Apr 03, 2024 $153.53 $154.12 $150.79 $151.95 55 470
Apr 02, 2024 $155.51 $157.32 $152.70 $153.25 83 442
Apr 01, 2024 $156.87 $159.34 $152.77 $159.23 124 690
Click to get the best stock tips daily for free!

About BeiGene Ltd

BeiGene Ltd BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tu... BGNE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT